Kim, Dong-Wook
Saussele, Susanne
Williams, Loretta A.
Mohamed, Hesham
Rong, Yuanxin
Zyczynski, Teresa
Pinilla-Ibarz, Javier
Abruzzese, Elisabetta
Funding for this research was provided by:
Bristol-Myers Squibb (N/A)
Article History
Received: 12 June 2017
Accepted: 7 March 2018
First Online: 20 March 2018
Compliance with ethical standards
:
: D-WK has received research funding and served on an advisory committee for ARIAD, Bristol-Myers Squibb, ILYANG, Novartis, Pfizer, and SUN Pharma. SS received research funding from Bristol-Myers Squibb and Novartis and has served as a consultant to Bristol-Myers Squibb, Incyte, Novartis, and Pfizer. LAW has received research funding from Bristol-Myers Squibb and Novartis and has served on an advisory committee for Bristol-Myers Squibb. JP-I has served as a consultant to ARIAD, Bristol-Myers Squibb, Novartis, and Pfizer, and served on a speaker’s bureau for Bristol-Myers Squibb. EA has served as a consultant to ARIAD, Bristol-Myers Squibb, Novartis, and Pfizer. HM and TZ are employees of and have stock ownership in Bristol-Myers Squibb. YR was an employee of and has stock ownership in Bristol-Myers Squibb.
: This trial was approved by all institutional review boards and ethics committees.
: All patients gave written informed consent before enrollment, in accordance with the Declaration of Helsinki.